| 9001 | MANSC4 levels | GCST90469848 | 0.02 |
| 9002 | Freckles | GCST006091 | 0.02 |
| 9003 | JAM2/TGFBR2 ratio | GCST90315238 | 0.02 |
| 9004 | LILRB4 levels | GCST90469778 | 0.02 |
| 9005 | aparc-DKTatlas lh thickness precuneus | GCST90003563 | 0.02 |
| 9006 | CD79B/TNFRSF13B ratio | GCST90313902 | 0.02 |
| 9007 | HAVCR2 levels | GCST90469432 | 0.02 |
| 9008 | Diaphragmatic hernia (PheCode 550.2) | GCST90476061 | 0.02 |
| 9009 | FLT1/TFPI2 ratio | GCST90314856 | 0.02 |
| 9010 | IDP dMRI ProbtrackX MO str l | GCST90004023 | 0.02 |
| 9011 | CALB2 levels | GCST90468527 | 0.02 |
| 9012 | CD40LG/EGF ratio | GCST90313819 | 0.02 |
| 9013 | High-density lipoprotein levels (MTAG) | GCST90179147 | 0.02 |
| 9014 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 3) | GCST90320822 | 0.02 |
| 9015 | GC levels | GCST90162564 | 0.02 |
| 9016 | AMBP/HAVCR1 ratio | GCST90313254 | 0.02 |
| 9017 | ACY1/GSTA1 ratio | GCST90313163 | 0.02 |
| 9018 | HippSubfield lh volume Whole-hippocampal-body | GCST90002687 | 0.02 |
| 9019 | GART levels | GCST90469303 | 0.02 |
| 9020 | Dronedarone medication | FING00000474 | 0.02 |
| 9021 | FCN2 levels | GCST90469204 | 0.02 |
| 9022 | Serum 25-Hydroxyvitamin D levels (conditioned on BMI) | GCST90000616 | 0.02 |
| 9023 | Cholesterol to Total Lipids in Very Large HDL percentage | GCST90500324 | 0.02 |
| 9024 | Omega-3 fatty acids levels | GCST90499145 | 0.02 |
| 9025 | CCL5/TFPI ratio | GCST90313708 | 0.02 |
| 9026 | ENAH levels | GCST90469106 | 0.02 |
| 9027 | Diseases of hair and hair follicles (PheCode 704) | GCST90476209 | 0.02 |
| 9028 | FCER2/TNFRSF9 ratio | GCST90314791 | 0.02 |
| 9029 | DPP6/NRCAM ratio | GCST90314542 | 0.02 |
| 9030 | RELT/TNFRSF1A ratio | GCST90315767 | 0.02 |
| 9031 | KDR levels | GCST90243323 | 0.02 |
| 9032 | COX5B/METAP1D ratio | GCST90314201 | 0.02 |
| 9033 | White blood cell count | GCST90002407 | 0.02 |
| 9034 | CEACAM5 levels | GCST90468696 | 0.02 |
| 9035 | Phenylacetylcarnitine levels | GCST90199993 | 0.02 |
| 9036 | Lysoalkylphosphatidylcholine (O-20:0) levels | GCST90024193 | 0.02 |
| 9037 | Mean corpuscular volume | Blood count | UKBB00000449 | 0.02 |
| 9038 | T1 FreeSurfer aseg 3rd-Ventricle | GCST90384147 | 0.02 |
| 9039 | CC2D1A/STIP1 ratio | GCST90313665 | 0.02 |
| 9040 | PKLR/UBAC1 ratio | GCST90315660 | 0.02 |
| 9041 | Triacylglycerol (54:2) [NL-18:0] levels | GCST90025175 | 0.02 |
| 9042 | CD46/NID1 ratio | GCST90313833 | 0.02 |
| 9043 | Illness, injury, bereavement, stress in last 2 years - None of the above | Mental health | UKBB00000339 | 0.02 |
| 9044 | Sphinganine-1-phosphate levels | GCST90199845 | 0.02 |
| 9045 | CD27/NBL1 ratio | GCST90313774 | 0.02 |
| 9046 | Speech-in-noise perception | GCST90044776 | 0.02 |
| 9047 | aparc-Desikan lh volume parsopercularis | GCST90002785 | 0.02 |
| 9048 | Platelet distribution width | GCST004616 | 0.02 |
| 9049 | CRKL/DBNL ratio | GCST90314263 | 0.02 |
| 9050 | Other diseases of the respiratory system | FING00001011 | 0.02 |
| 9051 | Radial styloid tenosynovitis [de Quervain] | FING00001237 | 0.02 |
| 9052 | Paroxysmal supraventricular tachycardia (PheCode 427.11) | GCST90475964 | 0.02 |
| 9053 | STX16 levels | GCST90470769 | 0.02 |
| 9054 | Total Dihexosylceramide levels | GCST90025193 | 0.02 |
| 9055 | IDP dMRI TBSS ICVF Cerebral peduncle R | GCST90004341 | 0.02 |
| 9056 | Anomalies of dental arch relationship, including avohilmo | FING00000091 | 0.02 |
| 9057 | LAMA4 levels | GCST90469731 | 0.02 |
| 9058 | AZU1 levels | GCST90468408 | 0.02 |
| 9059 | GSTA3/KRT18 ratio | GCST90314997 | 0.02 |
| 9060 | CA4/TGFBR2 ratio | GCST90313588 | 0.02 |
| 9061 | Myocardial infarction | circulatory system | UKBB00000491 | 0.02 |
| 9062 | Phospholipids in HDL | GCST90497437 | 0.02 |
| 9063 | Total lipids in LDL (UKB data field 23425) | GCST90269522 | 0.02 |
| 9064 | C9 levels | GCST90468505 | 0.02 |
| 9065 | IDP dMRI ProbtrackX ICVF atr r | GCST90004378 | 0.02 |
| 9066 | CLEC1B/VTA1 ratio | GCST90314107 | 0.02 |
| 9067 | Cholesteryl Esters in Large LDL | GCST90497949 | 0.02 |
| 9068 | DKK4/REG1B ratio | GCST90314490 | 0.02 |
| 9069 | SWAP70 levels | GCST90242931 | 0.02 |
| 9070 | FGFBP2 levels | GCST90469231 | 0.02 |
| 9071 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502415 | 0.02 |
| 9072 | EFHD1 levels | GCST90469079 | 0.02 |
| 9073 | CFHR5 levels | GCST90468728 | 0.02 |
| 9074 | ING1 levels | GCST90469613 | 0.02 |
| 9075 | Arthropathy in ulcerative colitis | FING00000110 | 0.02 |
| 9076 | X-12844 levels | GCST90200523 | 0.02 |
| 9077 | red cell diameter width (RDW, maximum, inv-norm transformed) | GCST90476355 | 0.02 |
| 9078 | Risk taking | Mental health | UKBB00000759 | 0.02 |
| 9079 | ST8SIA1 levels | GCST90470754 | 0.02 |
| 9080 | Ever unenthusiastic/disinterested for a whole week | Mental health | UKBB00000226 | 0.02 |
| 9081 | Operation code - inguinal/femoral hernia repair | Operations | UKBB00000561 | 0.02 |
| 9082 | HippSubfield lh volume CA4-body | GCST90002683 | 0.02 |
| 9083 | CCL5/SELP ratio | GCST90313705 | 0.02 |
| 9084 | IDP dMRI TBSS ICVF Anterior limb of internal capsule R | GCST90004343 | 0.02 |
| 9085 | EREG levels | GCST90469145 | 0.02 |
| 9086 | TNFSF10 levels | GCST90274843 | 0.02 |
| 9087 | Total lipids in small LDL (UKB data field 23545) | GCST90269642 | 0.02 |
| 9088 | IFNGR1 levels | GCST90469513 | 0.02 |
| 9089 | CD1C levels | GCST90468604 | 0.02 |
| 9090 | aparc-Desikan lh thickness precuneus | GCST90003469 | 0.02 |
| 9091 | PRCP levels | GCST90470314 | 0.02 |
| 9092 | Mackerel liking | GCST90094796 | 0.02 |
| 9093 | CD209/CLEC4G ratio | GCST90313750 | 0.02 |
| 9094 | aseg rh intensity Putamen | GCST90003784 | 0.02 |
| 9095 | PBXIP1 levels | GCST90470164 | 0.02 |
| 9096 | Total Cholesteryl ester levels | GCST90025188 | 0.02 |
| 9097 | IDP dMRI ProbtrackX ISOVF cgc l | GCST90004529 | 0.02 |
| 9098 | UPB1 levels | GCST90471013 | 0.02 |
| 9099 | Moderate-to-vigorous intensity physical activity during leisure time | GCST90104341 | 0.02 |
| 9100 | Types of physical activity in last 4 weeks - None of the above | Physical activity | UKBB00000872 | 0.02 |
| 9101 | OSM/TGFA ratio | GCST90315590 | 0.02 |
| 9102 | BDNF levels | GCST90468437 | 0.02 |
| 9103 | X-25371 levels | GCST90200656 | 0.02 |
| 9104 | IDP dMRI ProbtrackX L1 ptr l | GCST90004265 | 0.02 |
| 9105 | FCGR3B levels | GCST90469202 | 0.02 |
| 9106 | BSG/IL12A_IL12B ratio | GCST90313532 | 0.02 |
| 9107 | CCN2/TACC3 ratio | GCST90313717 | 0.02 |
| 9108 | Handedness (chirality/laterality) - Left-handed | Early life factors | UKBB00000302 | 0.02 |
| 9109 | Cholesteryl Esters to Total Lipids in Very Large HDL percentage | GCST90500359 | 0.02 |
| 9110 | TRIM25 levels | GCST90470966 | 0.02 |
| 9111 | Nonalcoholic steatohepatitis | FING00000879 | 0.02 |
| 9112 | Long-standing illness, disability or infirmity | General health | UKBB00000409 | 0.02 |
| 9113 | Smoking status - Previous | Smoking | UKBB00000781 | 0.02 |
| 9114 | Neutrophil percentage of white cells variance | GCST90565701 | 0.02 |
| 9115 | APP/EGF ratio | GCST90313322 | 0.02 |
| 9116 | Late-onset myasthenia gravis | GCST90432158 | 0.02 |
| 9117 | Herring liking | GCST90094781 | 0.02 |
| 9118 | Diacylglycerol_44:6_[M+H-H2O]1+ levels | GCST90060245 | 0.02 |
| 9119 | CEP170 levels | GCST90468711 | 0.02 |
| 9120 | Urine N-acetylglutamate levels in chronic kidney disease | GCST90265569 | 0.02 |
| 9121 | Other specified and unspecified disorders of lens | FING00001101 | 0.02 |
| 9122 | Epilepsy | FING00000511 | 0.02 |
| 9123 | Clonal haematopoiesis of indeterminate potential (ASXL1 mutation) | GCST90165259 | 0.02 |
| 9124 | DOK2/FADD ratio | GCST90314530 | 0.02 |
| 9125 | Papillary adenocarcinoma of thyroid gland, excluding all cancers (controls excluding all cancers) | FING00001143 | 0.02 |
| 9126 | Glycated hemoglobin levels | GCST90002244 | 0.02 |
| 9127 | CRELD2 levels | GCST90468859 | 0.02 |
| 9128 | GABBR2 levels | GCST90241230 | 0.02 |
| 9129 | Recent inability to stop or control worrying | Anxiety | UKBB00000742 | 0.02 |
| 9130 | HEXIM1/NT5C3A ratio | GCST90315048 | 0.02 |
| 9131 | FABP1/FABP2 ratio | GCST90314750 | 0.02 |
| 9132 | Hypotaurine levels | GCST90200379 | 0.02 |
| 9133 | Right-hemisphere limbic network to putamen white-matter structural connectivity | GCST90302829 | 0.02 |
| 9134 | Urinary calculus | genitourinary | UKBB00000886 | 0.01 |
| 9135 | Total lipid levels in very large HDL | GCST90093010 | 0.01 |
| 9136 | Left ventricular end diastole inferolateral wall thickness | GCST90278516 | 0.01 |
| 9137 | FOXO1/NFATC1 ratio | GCST90314873 | 0.01 |
| 9138 | red blood cell count (RBC, mean, inv-norm transformed) | GCST90476347 | 0.01 |
| 9139 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T494 | ECGA000494 | 0.01 |
| 9140 | monocyte (fraction, mean, inv-norm transformed) | GCST90475511 | 0.01 |
| 9141 | MSLN levels | GCST90469948 | 0.01 |
| 9142 | CXCL5/PLXNA4 ratio | GCST90314351 | 0.01 |
| 9143 | Cholesterol in small LDL (UKB data field 23547) | GCST90269644 | 0.01 |
| 9144 | Chronic dermatitis due to solar radiation (PheCode 938.2) | GCST90476288 | 0.01 |
| 9145 | Dihomo-linoleoylcarnitine (C20:2) levels | GCST90200144 | 0.01 |
| 9146 | EREG/TIMP3 ratio | GCST90314708 | 0.01 |
| 9147 | Plasma sulfate of piperine metabolite C18H21NO3 (1)* levels in chronic kidney disease | GCST90266016 | 0.01 |
| 9148 | Neuroendocrine tumor and carcinoma of small intestine, excluding all cancers (controls excluding all cancers) | FING00000865 | 0.01 |
| 9149 | Blood cell traits latent factor 5 (platelet) | GCST90559247 | 0.01 |
| 9150 | Milk type used: Full cream (UKB data field 1418_1) | GCST90132938 | 0.01 |
| 9151 | GMPR levels | GCST90469368 | 0.01 |
| 9152 | Diseases of sebaceous glands (PheCode 706) | GCST90476210 | 0.01 |
| 9153 | CST3/RARRES2 ratio | GCST90314295 | 0.01 |
| 9154 | Right-hemisphere salience/ventral attention network to hippocampus white-matter structural connectivity | GCST90302821 | 0.01 |
| 9155 | Length of working week for main job | Employment | UKBB00000405 | 0.01 |
| 9156 | high density lipoprotein cholesterol (HDLC, maximum, inv-norm transformed) | GCST90475348 | 0.01 |
| 9157 | T1 CAT volume L VIIIb | GCST90384130 | 0.01 |
| 9158 | Ceramide (d16:1/22:0) levels | GCST90024026 | 0.01 |
| 9159 | FXYD5/TMSB10 ratio | GCST90314906 | 0.01 |
| 9160 | Thyroid peroxidase antibody positivity with euthyroid in pregnancy | GCST90435203 | 0.01 |
| 9161 | TPPP3 levels | GCST90470948 | 0.01 |
| 9162 | Insomnia | FING00000683 | 0.01 |
| 9163 | DFFA/SIRT2 ratio | GCST90314462 | 0.01 |
| 9164 | PMVK/PRDX5 ratio | GCST90315694 | 0.01 |
| 9165 | Cereal type - Other (e.g. Cornflakes, Frosties) | Diet | UKBB00000125 | 0.01 |
| 9166 | mean platelet volume (MPV, maximum, inv-norm transformed) | GCST90475517 | 0.01 |
| 9167 | Treatment/medication code - seretide 50 evohaler | Medications | UKBB00000858 | 0.01 |
| 9168 | Macular degeneration, dry (PheCode 362.21) | GCST90475851 | 0.01 |
| 9169 | CPPED1 levels | GCST90468845 | 0.01 |
| 9170 | BPIFB1 levels | GCST90468462 | 0.01 |
| 9171 | MIF levels | GCST90089018 | 0.01 |
| 9172 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 8) | GCST90320827 | 0.01 |
| 9173 | DSCAM levels | GCST90469041 | 0.01 |
| 9174 | CD84/SDC4 ratio | GCST90313916 | 0.01 |
| 9175 | FAM3B/GUCA2A ratio | GCST90314779 | 0.01 |
| 9176 | IDP T1 FAST ROIs brain stem | GCST90002561 | 0.01 |
| 9177 | Phosphatidylcholine (40:8) levels | GCST90024299 | 0.01 |
| 9178 | PTPRK levels | GCST90470383 | 0.01 |
| 9179 | LYN/YES1 ratio | GCST90315351 | 0.01 |
| 9180 | Collagenous colitis | GCST90204145 | 0.01 |
| 9181 | Glucose levels | GCST90132724 | 0.01 |
| 9182 | AHCY/HSPA1A ratio | GCST90313211 | 0.01 |
| 9183 | ANGPT1/SERPINE1 ratio | GCST90313269 | 0.01 |
| 9184 | CC2D1A/STAMBP ratio | GCST90313664 | 0.01 |
| 9185 | Other localized connective tissue disorders | FING00001066 | 0.01 |
| 9186 | Monocyte count | GCST90002393 | 0.01 |
| 9187 | Biological Mother: Cancer, Breast | GCST90475485 | 0.01 |
| 9188 | Worry | GCST006478 | 0.01 |
| 9189 | T1 FreeSurfer a2009s lh S temporal sup area | GCST90384740 | 0.01 |
| 9190 | F2R/SEMA4D ratio | GCST90314734 | 0.01 |
| 9191 | CXCL8 levels | GCST90468934 | 0.01 |
| 9192 | Skin colour | Sun exposure | UKBB00000773 | 0.01 |
| 9193 | X-12038 levels | GCST90243683 | 0.01 |
| 9194 | rfMRI connectivity (ICA100 edge 387) | GCST90005240 | 0.01 |
| 9195 | RTN4IP1 levels | GCST90470507 | 0.01 |
| 9196 | Glycosyl-N-behenoyl-sphingadienine (d18:2/22:0) levels | GCST90200105 | 0.01 |
| 9197 | Two-hour glucose | GCST90002227 | 0.01 |
| 9198 | Dissociative [conversion] disorders | FING00000468 | 0.01 |
| 9199 | Macular cyst | FING00000743 | 0.01 |
| 9200 | KIF22 levels | GCST90469682 | 0.01 |
| 9201 | CST3/DEFA1_DEFA1B ratio | GCST90314291 | 0.01 |
| 9202 | Sphingomyelin (d18:1/14:0) levels/Sphingomyelin (d16:1/16:0) levels | GCST90025743 | 0.01 |
| 9203 | Serum creatinine levels | GCST90018759 | 0.01 |
| 9204 | CD163/MARCO ratio | GCST90313737 | 0.01 |
| 9205 | FGFR2/TGFBR2 ratio | GCST90314813 | 0.01 |
| 9206 | Cleft hard palate NOS | FING00000306 | 0.01 |
| 9207 | Blood cell traits latent factor 18 (platelet) | GCST90559260 | 0.01 |
| 9208 | SERPINE1/VASH1 ratio | GCST90315836 | 0.01 |
| 9209 | IGF1R levels | GCST90469524 | 0.01 |
| 9210 | CA4/FOLR2 ratio | GCST90313585 | 0.01 |
| 9211 | monocyte (fraction, maximum, inv-norm transformed) | GCST90475508 | 0.01 |
| 9212 | Worrier / anxious feelings | Mental health | UKBB00000921 | 0.01 |
| 9213 | CFHR2 levels | GCST90468726 | 0.01 |
| 9214 | Right-hemisphere control network to hippocampus white-matter structural connectivity | GCST90302840 | 0.01 |
| 9215 | Frailty (Factor 6 - Disability) | GCST90624052 | 0.01 |
| 9216 | RAPGEF2 levels | GCST90470426 | 0.01 |
| 9217 | PINLYP levels | GCST90470238 | 0.01 |
| 9218 | Nonsuppurative otitis media | FING00000885 | 0.01 |
| 9219 | T1 FreeSurfer a2009s rh S temporal sup area | GCST90384962 | 0.01 |
| 9220 | CD69/TIA1 ratio | GCST90313888 | 0.01 |
| 9221 | ARHGAP25 levels | GCST90468353 | 0.01 |
| 9222 | Lysoalkylphosphatidylcholine (O-22:0) levels | GCST90025434 | 0.01 |
| 9223 | X-12510--2-aminooctanoic acid levels | GCST90243748 | 0.01 |
| 9224 | 1-methylhistidine levels | GCST90199691 | 0.01 |
| 9225 | Lysoalkenylphosphatidylethanolamine (P-20:0) levels | GCST90025460 | 0.01 |
| 9226 | Non-cancer illness code, self-reported - depression | Medical conditions | UKBB00000507 | 0.01 |
| 9227 | Carboplatin drug response (IC50) | GCST90011783 | 0.01 |
| 9228 | Sphingomyelins levels (UKB data field 23438) | GCST90269535 | 0.01 |
| 9229 | Fed-up feelings | Mental health | UKBB00000242 | 0.01 |
| 9230 | Breast cancer | GCST004988 | 0.01 |
| 9231 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T489 | ECGA000489 | 0.01 |
| 9232 | Keloid | GCST90018654 | 0.01 |
| 9233 | AXIN1/DOK2 ratio | GCST90313406 | 0.01 |
| 9234 | Right-hemisphere limbic network to caudate white-matter structural connectivity | GCST90302828 | 0.01 |
| 9235 | Gestational [pregnancy-induced] hypertension | FING00000571 | 0.01 |
| 9236 | rfMRI connectivity (ICA100 edge 1011) | GCST90005864 | 0.01 |
| 9237 | Salty food liking | GCST90094828 | 0.01 |
| 9238 | MZB1 levels | GCST90469987 | 0.01 |
| 9239 | Mean corpuscular volume (UKB data field 30040) | GCST90468086 | 0.01 |
| 9240 | PAXX levels | GCST90470161 | 0.01 |
| 9241 | CKAP2 levels | GCST90240866 | 0.01 |
| 9242 | Psoriasis | GCST90468147 | 0.01 |
| 9243 | CFHR4 levels | GCST90468727 | 0.01 |
| 9244 | TNFRSF19 levels | GCST90470909 | 0.01 |
| 9245 | CLEC7A levels | GCST90468778 | 0.01 |
| 9246 | Current employment status - Retired | Employment | UKBB00000159 | 0.01 |
| 9247 | CAMK1D levels | GCST90240556 | 0.01 |
| 9248 | Lymphoid leukaemia (controls excluding all cancers) | FING00000741 | 0.01 |
| 9249 | TNFRSF6B levels | GCST90470914 | 0.01 |
| 9250 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T441 | ECGU000441 | 0.01 |
| 9251 | CD83/TREM2 ratio | GCST90313908 | 0.01 |
| 9252 | Phospholipids to total lipids in medium LDL percentage (UKB data field 23619) | GCST90269716 | 0.01 |
| 9253 | Maternal care for other conditions predominantly related to pregnancy | FING00000791 | 0.01 |
| 9254 | Monocyte percentage of white cells | GCST90002394 | 0.01 |
| 9255 | ATF6 levels | GCST90617260 | 0.01 |
| 9256 | Recent feelings of foreboding | Anxiety | UKBB00000738 | 0.01 |
| 9257 | Left-hemisphere dorsal attention network to right-hemisphere salience/ventral attention network white-matter structural connectivity | GCST90302697 | 0.01 |
| 9258 | LAMP3/PRSS8 ratio | GCST90315275 | 0.01 |
| 9259 | METAP1D/PLXNA4 ratio | GCST90315427 | 0.01 |
| 9260 | Colitis, primary sclerosing, strict definition | FING00000313 | 0.01 |
| 9261 | Cerebrospinal fluid 5-methylthioadenosine (MTA) levels | GCST90318216 | 0.01 |
| 9262 | Myocardial fractal dimension (slice 6) | GCST90000292 | 0.01 |
| 9263 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 2) | GCST90320821 | 0.01 |
| 9264 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T493 | ECGA000493 | 0.01 |
| 9265 | Basophil count | GCST90002292 | 0.01 |
| 9266 | CR2 levels | GCST90468852 | 0.01 |
| 9267 | PLXNA4/VASH1 ratio | GCST90315691 | 0.01 |
| 9268 | Vegetarianism | GCST90428838 | 0.01 |
| 9269 | KLK6 levels | GCST90012008 | 0.01 |
| 9270 | GNS levels | GCST90088460 | 0.01 |
| 9271 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T498 | ECGA000498 | 0.01 |
| 9272 | CIAPIN1/SNX9 ratio | GCST90314068 | 0.01 |
| 9273 | TSPAN1 levels | GCST90470978 | 0.01 |
| 9274 | Raw carrot liking | GCST90094818 | 0.01 |
| 9275 | Activities undertaken to treat anxiety | Anxiety | UKBB00000009 | 0.01 |
| 9276 | Plum liking | GCST90094812 | 0.01 |
| 9277 | Atrophic disorders of skin | FING00000129 | 0.01 |
| 9278 | NFE2 levels | GCST90470035 | 0.01 |
| 9279 | Undecenoylcarnitine (C11:1) levels | GCST90200236 | 0.01 |
| 9280 | SPINT2/TNFSF13 ratio | GCST90315879 | 0.01 |
| 9281 | Triglycerides in large HDL | GCST90497882 | 0.01 |
| 9282 | DTI TBSS L3 Superior fronto-occipital fasciculus R | GCST90384566 | 0.01 |
| 9283 | CABP2 levels | GCST90468519 | 0.01 |
| 9284 | HGF/TNFSF14 ratio | GCST90315060 | 0.01 |
| 9285 | AMBP/RARRES2 ratio | GCST90313256 | 0.01 |
| 9286 | Deforming dorsopathies | FING00000385 | 0.01 |
| 9287 | CEP43/TIA1 ratio | GCST90314021 | 0.01 |
| 9288 | CGA levels | GCST90468732 | 0.01 |
| 9289 | Lymphoplasmacytic lymphoma and Waldenstrom macroglobulinemia | GCST90624744 | 0.01 |
| 9290 | Conductive hearing loss (PheCode 389.2) | GCST90475912 | 0.01 |
| 9291 | CD40 levels | GCST90012065 | 0.01 |
| 9292 | Right-hemisphere control network to amygdala white-matter structural connectivity | GCST90302841 | 0.01 |
| 9293 | PAG1 levels | GCST90470147 | 0.01 |
| 9294 | EGLN1/LSP1 ratio | GCST90314617 | 0.01 |
| 9295 | T1 FreeSurfer BA lh BA2 exvivo volume | GCST90385534 | 0.01 |
| 9296 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 78) | GCST90320641 | 0.01 |
| 9297 | AGXT/GRPEL1 ratio | GCST90313205 | 0.01 |
| 9298 | Ulcer of lower limb, not elsewhere classified | FING00001385 | 0.01 |
| 9299 | ATOX1/SNAP29 ratio | GCST90313374 | 0.01 |
| 9300 | CD19 on IgD- CD27- B cell | GCST90001732 | 0.01 |
| 9301 | CCL7 levels | GCST90468585 | 0.01 |
| 9302 | FUT8/TNFSF14 ratio | GCST90314895 | 0.01 |
| 9303 | EGLN1/PIK3AP1 ratio | GCST90314619 | 0.01 |
| 9304 | Left-hemisphere default mode network to hippocampus white-matter structural connectivity | GCST90302771 | 0.01 |
| 9305 | EIF2AK2 levels | GCST90469091 | 0.01 |
| 9306 | DTI TBSS L3 Cingulum hippocampus L | GCST90384561 | 0.01 |
| 9307 | 5-oxoproline levels | GCST90243437 | 0.01 |
| 9308 | CTSS levels | GCST90468916 | 0.01 |
| 9309 | MNDA/NCF2 ratio | GCST90315472 | 0.01 |
| 9310 | KLRB1 levels | GCST90469709 | 0.01 |
| 9311 | FSTL3/SPON2 ratio | GCST90314884 | 0.01 |
| 9312 | Triacylglycerol_50:4_[M+NH4]1+ levels | GCST90060466 | 0.01 |
| 9313 | Takes medication for Thyroid problems? | GCST90475277 | 0.01 |
| 9314 | Feeling miserable | GCST006943 | 0.01 |
| 9315 | Phospholipids in medium LDL (UKB data field 23539) | GCST90269636 | 0.01 |
| 9316 | NIT1 levels | GCST90470050 | 0.01 |
| 9317 | Ulcerative rectosigmoiditis | FING00001394 | 0.01 |
| 9318 | Illnesses of siblings - High blood pressure | Family history | UKBB00000352 | 0.01 |
| 9319 | HippSubfield lh volume molecular-layer-HP-head | GCST90002677 | 0.01 |
| 9320 | Pancreas iron content | GCST90016676 | 0.01 |
| 9321 | DTI TBSS L1 Cingulum cingulate gyrus L | GCST90384463 | 0.01 |
| 9322 | Placental weight (maternal genotype, adjusted for sex and gestational age) | GCST90275190 | 0.01 |
| 9323 | Graves disease, strict definition | FING00000592 | 0.01 |
| 9324 | RLN2 levels | GCST90470474 | 0.01 |
| 9325 | Ceramide (d17:1/22:0) levels | GCST90024032 | 0.01 |
| 9326 | Urolithiasis | GCST90018715 | 0.01 |
| 9327 | DSG3/SPINK5 ratio | GCST90314561 | 0.01 |
| 9328 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 86) | GCST90320649 | 0.01 |
| 9329 | Calculus of kidney | genitourinary | UKBB00000115 | 0.01 |
| 9330 | Rhodanobacter abundance in stool | GCST90032536 | 0.01 |
| 9331 | Generalized anxiety disorder | FING00000566 | 0.01 |
| 9332 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T497 | ECGA000497 | 0.01 |
| 9333 | GP2 levels | GCST90469382 | 0.01 |
| 9334 | Placental weight (maternal genotype, adjusted for sex) | GCST90275198 | 0.01 |
| 9335 | Obesity | FING00000895 | 0.01 |
| 9336 | Other disorders of eyelids (PheCode 374) | GCST90475890 | 0.01 |
| 9337 | CCL22 levels | GCST90468574 | 0.01 |
| 9338 | Bilirubin (E,Z or Z,E) levels | GCST90243750 | 0.01 |
| 9339 | Valine levels (UKB data field 23467) | GCST90269564 | 0.01 |
| 9340 | Treatment/medication code - perindopril | Medications | UKBB00000854 | 0.01 |
| 9341 | ICD10 C53: Malignant neoplasm of cervix uteri | GCST90454202 | 0.01 |
| 9342 | Cholesteryl ester levels in large HDL | GCST90092846 | 0.01 |
| 9343 | Pregnenetriol sulfate levels | GCST90200241 | 0.01 |
| 9344 | TNFSF12/TNFSF13 ratio | GCST90315941 | 0.01 |
| 9345 | Statin-associated type 2 diabetes mellitus | GCST90652517 | 0.01 |
| 9346 | EBAG9/FKBP5 ratio | GCST90314564 | 0.01 |
| 9347 | AKR7L levels | GCST90468275 | 0.01 |
| 9348 | Contracture of palmar fascia [Dupuytren's disease] (PheCode 728.71) | GCST90476245 | 0.01 |
| 9349 | MSRA/SNAP29 ratio | GCST90315500 | 0.01 |
| 9350 | CSF1/IFNGR1 ratio | GCST90314283 | 0.01 |
| 9351 | Subarachnoid hemorrhage | GCST90018703 | 0.01 |
| 9352 | MB levels | GCST90012047 | 0.01 |
| 9353 | PARP1/TCL1A ratio | GCST90315602 | 0.01 |
| 9354 | rfMRI amplitudes (ICA100 node 15) | GCST90004603 | 0.01 |
| 9355 | TMSB10/TRIAP1 ratio | GCST90315924 | 9.99e-03 |
| 9356 | CD99L2/RARRES2 ratio | GCST90313927 | 9.99e-03 |
| 9357 | Ceramide (d16:1/24:0) levels | GCST90025266 | 9.98e-03 |
| 9358 | Coagulation defects (PheCode 286) | GCST90475796 | 9.97e-03 |
| 9359 | ENO2/PLXNA4 ratio | GCST90314665 | 9.97e-03 |
| 9360 | INPP5J levels | GCST90469618 | 9.91e-03 |
| 9361 | PSTPIP2 levels | GCST90470366 | 9.91e-03 |
| 9362 | triglyceride (maximum, inv-norm transformed) | GCST90476429 | 9.89e-03 |
| 9363 | ST6GALNAC2 levels | GCST90240251 | 9.87e-03 |
| 9364 | IDP T1 SIENAX CSF normalised volume | GCST90002428 | 9.84e-03 |
| 9365 | AAGAB levels | GCST90617473 | 9.83e-03 |
| 9366 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T445 | ECGU000445 | 9.81e-03 |
| 9367 | PCDH17/SEMA7A ratio | GCST90315605 | 9.80e-03 |
| 9368 | Diabetes mellitus | endocrine/metabolic | UKBB00000169 | 9.80e-03 |
| 9369 | Total Alkenylphosphatidylcholine levels | GCST90025835 | 9.77e-03 |
| 9370 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T439 | ECGU000439 | 9.75e-03 |
| 9371 | EFNA4/VWC2 ratio | GCST90314607 | 9.74e-03 |
| 9372 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 87) | GCST90320906 | 9.74e-03 |
| 9373 | NBN levels | GCST90470002 | 9.72e-03 |
| 9374 | RILP/RWDD1 ratio | GCST90315778 | 9.72e-03 |
| 9375 | DNMBP/TBC1D5 ratio | GCST90314519 | 9.72e-03 |
| 9376 | PPL levels | GCST90470294 | 9.69e-03 |
| 9377 | NDUFB7 levels | GCST90470015 | 9.69e-03 |
| 9378 | Omega-3 fatty acids to total fatty acids percentage | GCST90502448 | 9.67e-03 |
| 9379 | Cereal type: Other (e.g. Cornflakes, Frosties) (UKB data field 1468_5) | GCST90132973 | 9.63e-03 |
| 9380 | IL1R1 levels | GCST90425563 | 9.58e-03 |
| 9381 | Triacylglycerol (54:1) [NL-18:1] levels | GCST90024563 | 9.58e-03 |
| 9382 | SLC27A4/TDRKH ratio | GCST90315851 | 9.49e-03 |
| 9383 | Total lipids in very large HDL | GCST90500410 | 9.48e-03 |
| 9384 | TRIM24 levels | GCST90470965 | 9.48e-03 |
| 9385 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 36) | GCST90320855 | 9.46e-03 |
| 9386 | IL4R levels | GCST90469598 | 9.38e-03 |
| 9387 | SELP/VSIR ratio | GCST90315822 | 9.35e-03 |
| 9388 | Concentration of small HDL particles | GCST90499464 | 9.35e-03 |
| 9389 | BPIFB1/GLRX ratio | GCST90313530 | 9.34e-03 |
| 9390 | CCN2/VEGFC ratio | GCST90313719 | 9.34e-03 |
| 9391 | IDP T1 SIENAX CSF unnormalised volume | GCST90002429 | 9.33e-03 |
| 9392 | GZMB/IL15 ratio | GCST90315015 | 9.32e-03 |
| 9393 | Hair colour (natural, before greying): Blonde (UKB data field 1747_1) | GCST90041836 | 9.29e-03 |
| 9394 | aparc-DKTatlas lh volume parsopercularis | GCST90002878 | 9.27e-03 |
| 9395 | MZT1 levels | GCST90469988 | 9.27e-03 |
| 9396 | mean corpuscular hemoglobin (MCH, minimum, inv-norm transformed) | GCST90475448 | 9.26e-03 |
| 9397 | Irritability | Mental health | UKBB00000380 | 9.26e-03 |
| 9398 | CC2D1A levels | GCST90468557 | 9.26e-03 |
| 9399 | Citrate levels | GCST90497206 | 9.22e-03 |
| 9400 | Sphingomyelin (d16:1/23:0) levels/Sphingomyelin (d17:1/22:0) levels | GCST90025735 | 9.20e-03 |
| 9401 | TACC3/TRIAP1 ratio | GCST90315901 | 9.17e-03 |
| 9402 | CD164/NUDT5 ratio | GCST90313742 | 9.14e-03 |
| 9403 | CDC37/SNAP29 ratio | GCST90313935 | 9.14e-03 |
| 9404 | Phospholipids to total lipids ratio in small HDL | GCST90092953 | 9.12e-03 |
| 9405 | HMOX2/TDRKH ratio | GCST90315067 | 9.12e-03 |
| 9406 | TACSTD2 levels | GCST90470798 | 9.04e-03 |
| 9407 | Docosahexaenoic acid to total fatty acids percentage | GCST90502268 | 9.04e-03 |
| 9408 | Atrial fibrillation/atrial flutter | GCST90018576 | 9.03e-03 |
| 9409 | CDSN/KLK8 ratio | GCST90313996 | 9.03e-03 |
| 9410 | IL34 levels | GCST90469593 | 9.02e-03 |
| 9411 | CD274 levels | GCST90274832 | 8.99e-03 |
| 9412 | CDH5/PEAR1 ratio | GCST90313959 | 8.98e-03 |
| 9413 | Alcohol drinker status - Never | Alcohol | UKBB00000022 | 8.98e-03 |
| 9414 | CD209/CLEC14A ratio | GCST90313749 | 8.98e-03 |
| 9415 | Phosphate levels | GCST90200393 | 8.95e-03 |
| 9416 | Bread intake (UKB data field 1438) | GCST90468162 | 8.94e-03 |
| 9417 | Chronic myeloproliferative disease | FING00000294 | 8.92e-03 |
| 9418 | Interpolated Age of participant when non-cancer illness first diagnosed | Medical conditions | UKBB00000369 | 8.85e-03 |
| 9419 | Dissection of aorta | FING00000467 | 8.83e-03 |
| 9420 | Total lipids in small HDL | GCST90499456 | 8.83e-03 |
| 9421 | chloride (mean, inv-norm transformed) | GCST90475194 | 8.81e-03 |
| 9422 | MANSC1/PODXL2 ratio | GCST90315371 | 8.80e-03 |
| 9423 | Use of sun/uv protection | Sun exposure | UKBB00000887 | 8.80e-03 |
| 9424 | PLXNA4/SKAP2 ratio | GCST90315685 | 8.80e-03 |
| 9425 | Concentration of very large HDL particles | GCST90500436 | 8.79e-03 |
| 9426 | SMTN levels | GCST90470689 | 8.79e-03 |
| 9427 | Medication use (glucocorticoids) | GCST90018780 | 8.79e-03 |
| 9428 | Hair colour (natural, before greying) - Blonde | Sun exposure | UKBB00000296 | 8.78e-03 |
| 9429 | Phospholipids to Total Lipids in Large HDL percentage | GCST90497863 | 8.78e-03 |
| 9430 | VSTM1 levels | GCST90471055 | 8.78e-03 |
| 9431 | IL6ST/PDGFRA ratio | GCST90315169 | 8.78e-03 |
| 9432 | CD36 levels | GCST90468627 | 8.76e-03 |
| 9433 | T1 FreeSurfer aseg Right-Pallidum | GCST90384164 | 8.74e-03 |
| 9434 | FADD/PTPN6 ratio | GCST90314775 | 8.69e-03 |
| 9435 | mean corpuscular hemoglobin (MCH, mean, inv-norm transformed) | GCST90475446 | 8.68e-03 |
| 9436 | AIFM1/EGF ratio | GCST90313219 | 8.67e-03 |
| 9437 | TNFSF11 levels | GCST90274844 | 8.64e-03 |
| 9438 | DECR1/MAP2K6 ratio | GCST90314447 | 8.59e-03 |
| 9439 | CASP8 levels | GCST90468548 | 8.56e-03 |
| 9440 | Fruit intake (weighted GWA) | GCST90267283 | 8.51e-03 |
| 9441 | Omega-3 fatty acids to total fatty acids percentage | GCST90502088 | 8.43e-03 |
| 9442 | Oily fish intake | Diet | UKBB00000547 | 8.43e-03 |
| 9443 | Operation code - cholecystectomy/gall bladder removal | Operations | UKBB00000554 | 8.42e-03 |
| 9444 | Bread consumption (slices per week) (UKB data field 1438) | GCST90132981 | 8.41e-03 |
| 9445 | L1CAM levels | GCST90469723 | 8.37e-03 |
| 9446 | Benign mammary dysplasia | FING00000151 | 8.37e-03 |
| 9447 | CRKL/PLA2G4A ratio | GCST90314271 | 8.36e-03 |
| 9448 | Asthma-related acute respiratory infections | FING00000117 | 8.35e-03 |
| 9449 | Degree of unsaturation | GCST90502224 | 8.33e-03 |
| 9450 | SEL1L levels | GCST90470564 | 8.31e-03 |
| 9451 | Other embolism and thrombosis | FING00001043 | 8.31e-03 |
| 9452 | CD40/IGSF8 ratio | GCST90313815 | 8.30e-03 |
| 9453 | Other retinal disorders | FING00001094 | 8.28e-03 |
| 9454 | Cholesteryl Esters to Total Lipids in Large HDL percentage | GCST90497763 | 8.27e-03 |
| 9455 | Wet age-related macular degeneration | FING00001448 | 8.27e-03 |
| 9456 | Myocardial fractal dimension (slice 4) | GCST90000290 | 8.23e-03 |
| 9457 | AFM levels | GCST90468249 | 8.22e-03 |
| 9458 | LSIL lesion of the cervix uteri | FING00000732 | 8.22e-03 |
| 9459 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T432 | ECGU000432 | 8.22e-03 |
| 9460 | Carotid plaque | GCST007435 | 8.19e-03 |
| 9461 | Cholesterol to Total Lipids in Large HDL percentage | GCST90497730 | 8.15e-03 |
| 9462 | DECR1/STX8 ratio | GCST90314452 | 8.15e-03 |
| 9463 | RBP5 levels | GCST90470439 | 8.13e-03 |
| 9464 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T442 | ECGU000442 | 8.12e-03 |
| 9465 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 30) | GCST90320849 | 8.12e-03 |
| 9466 | Feeling worry | GCST006950 | 8.10e-03 |
| 9467 | MAX/STK24 ratio | GCST90315404 | 8.09e-03 |
| 9468 | Malignant neoplasm of kidney, except pelvis (PheCode 189.11) | GCST90475597 | 8.08e-03 |
| 9469 | Hammer toe (acquired) (PheCode 735.21) | GCST90476250 | 8.08e-03 |
| 9470 | CKAP4 levels | GCST90468758 | 8.05e-03 |
| 9471 | RFC4 levels | GCST90470460 | 8.04e-03 |
| 9472 | FABP1/LGALS4 ratio | GCST90314752 | 8.03e-03 |
| 9473 | Salami liking | GCST90094825 | 8.03e-03 |
| 9474 | Other menopausal disorders | FING00001071 | 7.98e-03 |
| 9475 | N2-acetyl,N6,N6-dimethyllysine levels | GCST90200697 | 7.98e-03 |
| 9476 | SCLY/SORD ratio | GCST90315816 | 7.95e-03 |
| 9477 | DGKA levels | GCST90468989 | 7.93e-03 |
| 9478 | IBD (strict) with PSC | FING00000657 | 7.93e-03 |
| 9479 | Nasal polyps (PheCode 471) | GCST90476019 | 7.93e-03 |
| 9480 | aparc-Desikan rh area caudalmiddlefrontal | GCST90003110 | 7.89e-03 |
| 9481 | PEAR1/SCARF1 ratio | GCST90315642 | 7.87e-03 |
| 9482 | DOK2/SNX9 ratio | GCST90314539 | 7.83e-03 |
| 9483 | CD79B/FCRL1 ratio | GCST90313899 | 7.83e-03 |
| 9484 | Prostate cancer | GCST006085 | 7.82e-03 |
| 9485 | ELOA/MAD1L1 ratio | GCST90314640 | 7.82e-03 |
| 9486 | Zoster infection | GCST90018721 | 7.81e-03 |
| 9487 | KIRREL2 levels | GCST90469690 | 7.81e-03 |
| 9488 | HippSubfield lh volume GC-ML-DG-body | GCST90002681 | 7.78e-03 |
| 9489 | Right-hemisphere limbic network to thalamus white-matter structural connectivity | GCST90302827 | 7.77e-03 |
| 9490 | Turnip liking | GCST90094861 | 7.76e-03 |
| 9491 | IL19 levels | GCST90469568 | 7.75e-03 |
| 9492 | CLK2 levels | GCST90240975 | 7.73e-03 |
| 9493 | 4-androsten-3beta,17beta-diol disulfate 1 levels | GCST90243879 | 7.72e-03 |
| 9494 | Nasal polyps | respiratory | UKBB00000494 | 7.71e-03 |
| 9495 | Phenylacetylglutamate levels | GCST90200069 | 7.70e-03 |
| 9496 | PTPRF/SDC1 ratio | GCST90315752 | 7.68e-03 |
| 9497 | KCTD5 levels | GCST90469670 | 7.68e-03 |
| 9498 | End-diastolic bi-ventricular shape (principal component 9) | GCST90448488 | 7.65e-03 |
| 9499 | 1-palmitoyl-2-linoleoyl-GPC (16:0/18:2) metabolite level | GCST90616405 | 7.65e-03 |
| 9500 | red blood cell count (RBC, mean, inv-norm transformed) | GCST90476349 | 7.61e-03 |
| 9501 | TYMP levels | GCST90470996 | 7.60e-03 |
| 9502 | CANT1/NUDT5 ratio | GCST90313619 | 7.59e-03 |
| 9503 | Length of time at current address | Household | UKBB00000404 | 7.59e-03 |
| 9504 | VEGFD levels | GCST90012069 | 7.58e-03 |
| 9505 | CXCL11/DKK1 ratio | GCST90314334 | 7.57e-03 |
| 9506 | Physical activity (Total log acceleration 8am-10am) | GCST90061413 | 7.54e-03 |
| 9507 | CDH5/ENG ratio | GCST90313954 | 7.53e-03 |
| 9508 | Benign neoplasm of colon, rectum, anus and anal canal | FING00000155 | 7.52e-03 |
| 9509 | Omega-3 fatty acids to total fatty acids percentage | GCST90502082 | 7.52e-03 |
| 9510 | Myocardial fractal dimension (slice 8) | GCST90000294 | 7.51e-03 |
| 9511 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T440 | ECGU000440 | 7.50e-03 |
| 9512 | Glaucoma | Glaucoma | UKBB00000286 | 7.47e-03 |
| 9513 | HSIL lesion of the cervix uteri, vagina or vulva | FING00000625 | 7.46e-03 |
| 9514 | Cholesterol levels in large HDL | GCST90092844 | 7.45e-03 |
| 9515 | DTI autoptx MD atr l tract | GCST90385222 | 7.39e-03 |
| 9516 | DEFA1_DEFA1B/LCN2 ratio | GCST90314454 | 7.38e-03 |
| 9517 | X-18922 levels | GCST90200578 | 7.37e-03 |
| 9518 | FABP3 levels | GCST90469175 | 7.36e-03 |
| 9519 | Propionylcarnitine levels | GCST90243593 | 7.35e-03 |
| 9520 | ICAM1/SELE ratio | GCST90315116 | 7.34e-03 |
| 9521 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T236 | ECGU000236 | 7.33e-03 |
| 9522 | Glomerular diseases | FING00000581 | 7.33e-03 |
| 9523 | Non-seminoma of testis, excluding all cancers (controls excluding all cancers) | FING00000874 | 7.31e-03 |
| 9524 | Internal derangement of knee (PheCode 835) | GCST90476282 | 7.27e-03 |
| 9525 | Birth asphyxia | FING00000218 | 7.26e-03 |
| 9526 | PTH levels | GCST90470372 | 7.25e-03 |
| 9527 | Linoleic acid levels | GCST90502009 | 7.25e-03 |
| 9528 | SEMA3F levels | GCST90470570 | 7.24e-03 |
| 9529 | CCL20 levels | GCST90012077 | 7.24e-03 |
| 9530 | FCER2/TREML2 ratio | GCST90314792 | 7.24e-03 |
| 9531 | Hypertrophic scar | FING00000642 | 7.22e-03 |
| 9532 | NXF1 levels | GCST90242149 | 7.20e-03 |
| 9533 | Prescriptions - paracetamol | antipyretic | UKBB00000696 | 7.19e-03 |
| 9534 | Prescriptions - antipyretic | UKBB00000665 | 7.19e-03 |
| 9535 | ThalamNuclei lh volume VPL | GCST90002717 | 7.19e-03 |
| 9536 | CTSO levels | GCST90179277 | 7.17e-03 |
| 9537 | Phospholipids to total lipids in IDL percentage (UKB data field 23609) | GCST90269706 | 7.17e-03 |
| 9538 | SPARCL1 levels | GCST90242870 | 7.17e-03 |
| 9539 | CXCL16 levels | GCST90468928 | 7.15e-03 |
| 9540 | Tobacco use | FING00001365 | 7.13e-03 |
| 9541 | MUC13 levels | GCST90469963 | 7.06e-03 |
| 9542 | Operative procedures - Angiocardiography of left side of heart NEC | Summary Operations | UKBB00000572 | 7.05e-03 |
| 9543 | UBA9475 sp002161235 abundance in stool | GCST90032635 | 7.04e-03 |
| 9544 | Mineral and other dietary supplements - Calcium | Medication | UKBB00000471 | 7.04e-03 |
| 9545 | Episcleritis | FING00000513 | 7.03e-03 |
| 9546 | Endometriosis of pelvic peritoneum | FING00000502 | 7.02e-03 |
| 9547 | Phospholipid levels in medium LDL | GCST90092912 | 6.95e-03 |
| 9548 | Gout, unspecified | FING00000589 | 6.95e-03 |
| 9549 | PRCP/SELE ratio | GCST90315726 | 6.94e-03 |
| 9550 | SCARF1/SUSD1 ratio | GCST90315811 | 6.92e-03 |
| 9551 | Hair colour (natural, before greying): Red (UKB data field 1747_2) | GCST90041837 | 6.91e-03 |
| 9552 | DRAXIN levels | GCST90469038 | 6.91e-03 |
| 9553 | Prurigo nodularis | FING00001220 | 6.88e-03 |
| 9554 | ADA2 levels | GCST90468215 | 6.85e-03 |
| 9555 | YOD1 levels | GCST90471090 | 6.85e-03 |
| 9556 | LY96/ST6GAL1 ratio | GCST90315348 | 6.85e-03 |
| 9557 | CNST/ITGB1BP2 ratio | GCST90314158 | 6.83e-03 |
| 9558 | ATXN10/PRTFDC1 ratio | GCST90313398 | 6.81e-03 |
| 9559 | CD14 levels | GCST90468598 | 6.80e-03 |
| 9560 | Late-onset myasthenia gravis | GCST90093466 | 6.77e-03 |
| 9561 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T496 | ECGA000496 | 6.77e-03 |
| 9562 | Spondyloarthritis | FING00001323 | 6.76e-03 |
| 9563 | CD46/SIAE ratio | GCST90313835 | 6.73e-03 |
| 9564 | Suffer from 'nerves' | Mental health | UKBB00000799 | 6.71e-03 |
| 9565 | Dihexosylceramide (d18:1/22:0) levels | GCST90025348 | 6.71e-03 |
| 9566 | FAM3B levels | GCST90469186 | 6.67e-03 |
| 9567 | LAYN levels | GCST90469742 | 6.65e-03 |
| 9568 | RGMB levels | GCST90470464 | 6.64e-03 |
| 9569 | Degree of unsaturation | GCST90502748 | 6.60e-03 |
| 9570 | Cholecystitis | FING00000274 | 6.60e-03 |
| 9571 | HippSubfield rh volume molecular-layer-HP-head | GCST90002699 | 6.58e-03 |
| 9572 | MVK/SERPINE1 ratio | GCST90315505 | 6.57e-03 |
| 9573 | Percentage of monosialylation of core-fucosylated monogalactosylated structures without bisecting GlcNAc (GP41) | GCST90668485 | 6.54e-03 |
| 9574 | MMP8/TGFA ratio | GCST90315466 | 6.53e-03 |
| 9575 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T492 | ECGA000492 | 6.53e-03 |
| 9576 | LTBR/TNFRSF14 ratio | GCST90315340 | 6.53e-03 |
| 9577 | PTS levels | GCST90470390 | 6.50e-03 |
| 9578 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T495 | ECGA000495 | 6.50e-03 |
| 9579 | CD59/CST6 ratio | GCST90313857 | 6.49e-03 |
| 9580 | IL15 levels | GCST90469556 | 6.48e-03 |
| 9581 | PPT1 levels | GCST90427718 | 6.47e-03 |
| 9582 | Irregular menses | FING00000701 | 6.47e-03 |
| 9583 | Other disorders of skin and subcutaneous tissue | FING00001035 | 6.46e-03 |
| 9584 | Melanomas of skin (PheCode 172.11) | GCST90475578 | 6.46e-03 |
| 9585 | Docosahexaenoic acid levels | GCST90501986 | 6.46e-03 |
| 9586 | STX6 levels | GCST90470774 | 6.45e-03 |
| 9587 | Muscular dystrophy | FING00000848 | 6.42e-03 |
| 9588 | White blood cell count | GCST90002374 | 6.42e-03 |
| 9589 | Interpolated Year when non-cancer illness first diagnosed | Medical conditions | UKBB00000371 | 6.40e-03 |
| 9590 | Cardiorespiratory fitness (vo2 max) | GCST90093317 | 6.38e-03 |
| 9591 | REN levels | GCST90012038 | 6.37e-03 |
| 9592 | Membranous nephropathy | GCST010006 | 6.36e-03 |
| 9593 | DAPP1/PMVK ratio | GCST90314396 | 6.36e-03 |
| 9594 | TLR4 levels | GCST90470880 | 6.35e-03 |
| 9595 | ALDH1A1/SORD ratio | GCST90313248 | 6.35e-03 |
| 9596 | Renal failure | FING00001250 | 6.34e-03 |
| 9597 | ANP32B levels | GCST90240176 | 6.34e-03 |
| 9598 | CRADD/STAMBP ratio | GCST90314244 | 6.33e-03 |
| 9599 | NOTCH2 levels | GCST90470066 | 6.31e-03 |
| 9600 | T1 FIRST volume L Puta | GCST90383987 | 6.31e-03 |
| 9601 | HTRA2/SNAP29 ratio | GCST90315098 | 6.30e-03 |
| 9602 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T438 | ECGU000438 | 6.29e-03 |
| 9603 | HEPACAM2 levels | GCST90469445 | 6.29e-03 |
| 9604 | CCL11 levels | GCST90468564 | 6.29e-03 |
| 9605 | 1,5-anhydroglucitol (1,5-ag) levels | GCST90243529 | 6.29e-03 |
| 9606 | Phospholipids to Total Lipids in Very Large HDL percentage | GCST90500474 | 6.27e-03 |
| 9607 | ADD1 levels | GCST90468233 | 6.26e-03 |
| 9608 | EBAG9/HBEGF ratio | GCST90314565 | 6.26e-03 |
| 9609 | COMP/TGFBI ratio | GCST90314192 | 6.23e-03 |
| 9610 | PGR levels | GCST90470223 | 6.22e-03 |
| 9611 | Insulin fold change during an oral glucose tolerance test | GCST90267568 | 6.21e-03 |
| 9612 | mean corpuscular hemoglobin (MCH, mean, inv-norm transformed) | GCST90475444 | 6.21e-03 |
| 9613 | Trigger finger | GCST90104907 | 6.18e-03 |
| 9614 | X-21286 levels | GCST90200562 | 6.17e-03 |
| 9615 | Rubneribacter sp002159915 abundance in stool | GCST90032541 | 6.15e-03 |
| 9616 | aparc-DKTatlas lh area superiorparietal | GCST90003261 | 6.14e-03 |
| 9617 | Right-hemisphere somatomotor network to amygdala white-matter structural connectivity | GCST90302799 | 6.14e-03 |
| 9618 | Phosphatidylcholine (40:8) levels | GCST90025538 | 6.13e-03 |
| 9619 | PLAUR levels | GCST90012051 | 6.13e-03 |
| 9620 | PFKFB2/SRP14 ratio | GCST90315650 | 6.12e-03 |
| 9621 | FADD/NCK2 ratio | GCST90314770 | 6.11e-03 |
| 9622 | CEBPB/PXN ratio | GCST90314008 | 6.10e-03 |
| 9623 | Asthma-related infections | FING00000118 | 6.05e-03 |
| 9624 | NRP2 levels | GCST90470086 | 6.03e-03 |
| 9625 | Citrate levels | GCST90092813 | 6.03e-03 |
| 9626 | aparc-Desikan lh area superiorparietal | GCST90003101 | 6.02e-03 |
| 9627 | GABARAPL1 levels | GCST90469287 | 6.01e-03 |
| 9628 | GALNT3 levels | GCST90469297 | 6.01e-03 |
| 9629 | Recent worrying too much about different things | Anxiety | UKBB00000746 | 6.01e-03 |
| 9630 | CCN3/PGF ratio | GCST90313722 | 6.00e-03 |
| 9631 | Major depressive disorder (probable) | GCST005904 | 6.00e-03 |
| 9632 | Plasma X-26054 levels in chronic kidney disease | GCST90266858 | 5.98e-03 |
| 9633 | Childhood sunburn occasions | Sun exposure | UKBB00000130 | 5.97e-03 |
| 9634 | PDCD5 levels | GCST90470182 | 5.97e-03 |
| 9635 | AHCY/FABP5 ratio | GCST90313208 | 5.97e-03 |
| 9636 | CA2/UBAC1 ratio | GCST90313583 | 5.95e-03 |
| 9637 | Docosahexaenoic acid to total fatty acids percentage | GCST90502284 | 5.94e-03 |
| 9638 | ATXN10 levels | GCST90468401 | 5.94e-03 |
| 9639 | Volume of right lateral nucleus | GCST90475039 | 5.93e-03 |
| 9640 | ASS1 levels | GCST90468380 | 5.93e-03 |
| 9641 | Urine glucosaminate levels in chronic kidney disease | GCST90265179 | 5.91e-03 |
| 9642 | Free Cholesterol to Total Lipids in Large HDL percentage | GCST90497793 | 5.89e-03 |
| 9643 | IL6ST/TYRO3 ratio | GCST90315170 | 5.88e-03 |
| 9644 | PPP1R12A/SPARC ratio | GCST90315712 | 5.86e-03 |
| 9645 | GP2/LGALS8 ratio | GCST90314961 | 5.86e-03 |
| 9646 | IRAG2 levels | GCST90469626 | 5.85e-03 |
| 9647 | DPP4 levels | GCST90469033 | 5.84e-03 |
| 9648 | CLEC4G/LGALS4 ratio | GCST90314120 | 5.84e-03 |
| 9649 | Leucine levels | GCST90243405 | 5.83e-03 |
| 9650 | PAMR1/RARRES2 ratio | GCST90315595 | 5.83e-03 |
| 9651 | KDM3A levels | GCST90469671 | 5.82e-03 |
| 9652 | B4GALT1/B4GAT1 ratio | GCST90313429 | 5.80e-03 |
| 9653 | CST6/FABP9 ratio | GCST90314301 | 5.79e-03 |
| 9654 | NMT1 levels | GCST90470059 | 5.79e-03 |
| 9655 | CR2/TNFRSF13B ratio | GCST90314225 | 5.79e-03 |
| 9656 | PPBP levels | GCST90470289 | 5.75e-03 |
| 9657 | LGALS4/TIE1 ratio | GCST90315316 | 5.75e-03 |
| 9658 | F-sweet food liking (derived food-liking factor) | GCST90094854 | 5.73e-03 |
| 9659 | Operation code - spinal laminectomy | Operations | UKBB00000564 | 5.72e-03 |
| 9660 | Right-hemisphere default mode network to amygdala white-matter structural connectivity | GCST90302849 | 5.71e-03 |
| 9661 | Liver enzyme levels (alkaline phosphatase) | GCST90013406 | 5.70e-03 |
| 9662 | rfMRI connectivity ICA-features 4 | GCST90006342 | 5.68e-03 |
| 9663 | Creatinine levels (UKB data field 23478) | GCST90269575 | 5.64e-03 |
| 9664 | CANT1 levels | GCST90468536 | 5.64e-03 |
| 9665 | Isolated hypothyroxinemia in pregnancy | GCST90435198 | 5.64e-03 |
| 9666 | Bacterial pneumoniae | FING00000139 | 5.63e-03 |
| 9667 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T435 | ECGU000435 | 5.62e-03 |
| 9668 | Ever smoked | Smoking | UKBB00000221 | 5.60e-03 |
| 9669 | AP1G2 levels | GCST90468323 | 5.59e-03 |
| 9670 | Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications | GCST90093113 | 5.59e-03 |
| 9671 | CELSR2 levels | GCST90468703 | 5.58e-03 |
| 9672 | RETN/RNASET2 ratio | GCST90315768 | 5.58e-03 |
| 9673 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T437 | ECGU000437 | 5.58e-03 |
| 9674 | PLAUR levels | GCST90470251 | 5.54e-03 |
| 9675 | Crohns disease | GCST90468121 | 5.54e-03 |
| 9676 | CRHBP/TREM2 ratio | GCST90314260 | 5.51e-03 |
| 9677 | Duration of heavy DIY | Physical activity | UKBB00000195 | 5.51e-03 |
| 9678 | CD164/SIAE ratio | GCST90313744 | 5.50e-03 |
| 9679 | Right-hemisphere salience/ventral attention network to putamen white-matter structural connectivity | GCST90302819 | 5.49e-03 |
| 9680 | 21-hydroxypregnenolone disulfate levels | GCST90199849 | 5.49e-03 |
| 9681 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T477 | ECGA000477 | 5.48e-03 |
| 9682 | Lysophosphatidylcholine (26:0) [sn2] levels | GCST90025428 | 5.45e-03 |
| 9683 | CDSN/NECTIN4 ratio | GCST90313998 | 5.44e-03 |
| 9684 | TRIM5 levels | GCST90470970 | 5.44e-03 |
| 9685 | Ceramide (d16:1/24:0) levels | GCST90024027 | 5.42e-03 |
| 9686 | RNASE4 levels | GCST90470478 | 5.41e-03 |
| 9687 | GSTA1/RBP5 ratio | GCST90314995 | 5.41e-03 |
| 9688 | PPP1R2/TMSB10 ratio | GCST90315721 | 5.40e-03 |
| 9689 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T476 | ECGA000476 | 5.40e-03 |
| 9690 | Acquired toe deformities (PheCode 735.2) | GCST90476249 | 5.39e-03 |
| 9691 | PTPRF/PTPRS ratio | GCST90315751 | 5.38e-03 |
| 9692 | wg lh intensity-contrast pericalcarine | GCST90003812 | 5.38e-03 |
| 9693 | CLMP/TNFRSF19 ratio | GCST90314136 | 5.37e-03 |
| 9694 | EIF4G1/TBC1D23 ratio | GCST90314639 | 5.37e-03 |
| 9695 | ADH4 levels | GCST90468244 | 5.36e-03 |
| 9696 | acne vulgaris | GCST90245818 | 5.34e-03 |
| 9697 | RBM17 levels | GCST90470434 | 5.34e-03 |
| 9698 | SLMAP levels | GCST90470673 | 5.33e-03 |
| 9699 | red cell diameter width (RDW, minimum, inv-norm transformed) | GCST90476363 | 5.29e-03 |
| 9700 | Frequency of depressed mood in last 2 weeks | Mental health | UKBB00000259 | 5.29e-03 |
| 9701 | CLU levels | GCST90468793 | 5.28e-03 |
| 9702 | LAP3 levels | GCST90469737 | 5.27e-03 |
| 9703 | Eye problems/disorders - Glaucoma | Eyesight | UKBB00000231 | 5.26e-03 |
| 9704 | Cholesteryl esters to total lipids in very large HDL percentage (UKB data field 23631) | GCST90269728 | 5.26e-03 |
| 9705 | Glomerular filtration rate in non diabetics (creatinine) | GCST003401 | 5.26e-03 |
| 9706 | Urea levels (UKB data field 30670) | GCST90468108 | 5.25e-03 |
| 9707 | TXN levels | GCST90470995 | 5.25e-03 |
| 9708 | Oral glucose tolerance test-2h | GCST90297790 | 5.21e-03 |
| 9709 | Total lipids in large HDL | GCST90497815 | 5.20e-03 |
| 9710 | SLC39A14 levels | GCST90470660 | 5.20e-03 |
| 9711 | Sleep apnoea, including avohilmo | FING00001310 | 5.17e-03 |
| 9712 | CCN2/EDAR ratio | GCST90313711 | 5.17e-03 |
| 9713 | COMMD1 levels | GCST90468825 | 5.16e-03 |
| 9714 | JCHAIN levels | GCST90469661 | 5.13e-03 |
| 9715 | SNAP25 levels | GCST90422083 | 5.12e-03 |
| 9716 | GET3 levels | GCST90469324 | 5.10e-03 |
| 9717 | ATOX1/TMSB10 ratio | GCST90313377 | 5.09e-03 |
| 9718 | Campesterol levels | GCST90199725 | 5.09e-03 |
| 9719 | 2-aminobutyrate levels | GCST90243584 | 5.08e-03 |
| 9720 | CA5A/GSTA1 ratio | GCST90313591 | 5.08e-03 |
| 9721 | TOR1AIP1 levels | GCST90470935 | 5.07e-03 |
| 9722 | Glaucoma | sense organs | UKBB00000287 | 5.04e-03 |
| 9723 | PDGFB/UXS1 ratio | GCST90315634 | 5.01e-03 |
| 9724 | POMC levels | GCST90470284 | 5.00e-03 |
| 9725 | PDGFRA levels | GCST90421093 | 5.00e-03 |
| 9726 | DSG4/FABP9 ratio | GCST90314562 | 4.99e-03 |
| 9727 | Total Phosphatidylcholine levels | GCST90025204 | 4.97e-03 |
| 9728 | KLK8 levels | GCST90469707 | 4.96e-03 |
| 9729 | MAP2K6/NT5C3A ratio | GCST90315374 | 4.96e-03 |
| 9730 | Type 1 diabetes, definitions combined | FING00001380 | 4.95e-03 |
| 9731 | EPPK1 levels | GCST90469137 | 4.95e-03 |
| 9732 | ALDH1A1 levels | GCST90468280 | 4.95e-03 |
| 9733 | Alkaline phosphatase (UKB data field 30610) | GCST90468060 | 4.94e-03 |
| 9734 | Cervical cancer | GCST90011816 | 4.93e-03 |
| 9735 | MLN/TNFRSF12A ratio | GCST90315459 | 4.93e-03 |
| 9736 | Malignant neoplasm of skin, excluding all cancers (controls excluding all cancers) | FING00000772 | 4.92e-03 |
| 9737 | Soft cheese liking | GCST90094843 | 4.92e-03 |
| 9738 | GCHFR levels | GCST90469317 | 4.92e-03 |
| 9739 | Basal cell carcinoma (PheCode 172.21) | GCST90475582 | 4.91e-03 |
| 9740 | Ceramide (d17:1/24:0) levels | GCST90024033 | 4.91e-03 |
| 9741 | AGXT/GSTA1 ratio | GCST90313206 | 4.91e-03 |
| 9742 | Degree of unsaturation | GCST90502233 | 4.91e-03 |
| 9743 | Volume of left central nucleus | GCST90474961 | 4.88e-03 |
| 9744 | CX3CL1/LAYN ratio | GCST90314325 | 4.88e-03 |
| 9745 | Glycated hemoglobin levels | GCST90566424 | 4.86e-03 |
| 9746 | 2-hydroxyisobutyrate levels | GCST90243539 | 4.85e-03 |
| 9747 | NCR3LG1 levels | GCST90470010 | 4.84e-03 |
| 9748 | DTI TBSS L2 Medial lemniscus L | GCST90384485 | 4.84e-03 |
| 9749 | HAMP levels | GCST90451683 | 4.82e-03 |
| 9750 | PLA2G4A/SPINT2 ratio | GCST90315671 | 4.82e-03 |
| 9751 | Cerebral aneurysm | GCST90018595 | 4.81e-03 |
| 9752 | Eosinophil count variance | GCST90565689 | 4.80e-03 |
| 9753 | Sphingomyelin (d18:1/16:0) levels | GCST90025744 | 4.79e-03 |
| 9754 | CLEC4C levels | GCST90468772 | 4.79e-03 |
| 9755 | Docosahexaenoic acid levels | GCST90502242 | 4.75e-03 |
| 9756 | Poisoning by antibiotics | injuries & poisonings | UKBB00000653 | 4.75e-03 |
| 9757 | Trauma (confirmatory factor analysis Factor 9) | GCST90309343 | 4.71e-03 |
| 9758 | Lysoalkylphosphatidylcholine (O-24:0) levels | GCST90025436 | 4.71e-03 |
| 9759 | F9/RARRES2 ratio | GCST90314749 | 4.70e-03 |
| 9760 | Autoimmune polyglandular failure | FING00000135 | 4.69e-03 |
| 9761 | 5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels | GCST90199854 | 4.69e-03 |
| 9762 | F-savoury food liking (derived food-liking factor) | GCST90094833 | 4.66e-03 |
| 9763 | HippSubfield lh volume presubiculum-head | GCST90002673 | 4.66e-03 |
| 9764 | CD69/PLXNA4 ratio | GCST90313880 | 4.63e-03 |
| 9765 | LGALS8/TXNDC5 ratio | GCST90315321 | 4.63e-03 |
| 9766 | HGF/PDGFB ratio | GCST90315058 | 4.62e-03 |
| 9767 | Milky sweets liking | GCST90094802 | 4.61e-03 |
| 9768 | ANXA10 levels | GCST90468314 | 4.60e-03 |
| 9769 | Symptoms involving digestive system (PheCode 561) | GCST90476069 | 4.59e-03 |
| 9770 | Omega-3 fatty acids to total fatty acids percentage | GCST90502451 | 4.58e-03 |
| 9771 | CD99L2/CPM ratio | GCST90313925 | 4.56e-03 |
| 9772 | Insulin fold change during an oral glucose tolerance test (adjusted for BMI) | GCST90267567 | 4.55e-03 |
| 9773 | DNAJB1/EIF4B ratio | GCST90314508 | 4.53e-03 |
| 9774 | EDAR/TREML2 ratio | GCST90314592 | 4.51e-03 |
| 9775 | SCG2 levels | GCST90470538 | 4.50e-03 |
| 9776 | CLEC1B/VSIR ratio | GCST90314106 | 4.50e-03 |
| 9777 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T446 | ECGU000446 | 4.49e-03 |
| 9778 | Cancer code, self-reported: breast cancer (UKB data field 20001_1002) | GCST90041886 | 4.48e-03 |
| 9779 | CLMP/TGFBR2 ratio | GCST90314135 | 4.46e-03 |
| 9780 | CD164/LGMN ratio | GCST90313741 | 4.45e-03 |
| 9781 | 1-arachidonoylglycerophosphocholine levels | GCST90243674 | 4.41e-03 |
| 9782 | Gout | GCST90399701 | 4.41e-03 |
| 9783 | Salad dressing liking | GCST90094822 | 4.38e-03 |
| 9784 | TNF/TNFRSF1B ratio | GCST90315942 | 4.37e-03 |
| 9785 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 44) | GCST90320607 | 4.36e-03 |
| 9786 | Free cholesterol to total lipids in small HDL percentage (UKB data field 23647) | GCST90269744 | 4.36e-03 |
| 9787 | Cancer of kidney and renal pelvis (PheCode 189.1) | GCST90475595 | 4.35e-03 |
| 9788 | Cheesecake liking | GCST90094730 | 4.35e-03 |
| 9789 | Loneliness (weighted GWA) | GCST90267289 | 4.33e-03 |
| 9790 | CCL14/CST3 ratio | GCST90313679 | 4.33e-03 |
| 9791 | Other malignant neoplasms of skin (=non-melanoma skin cancer), excluding all cancers (controls excluding all cancers) | FING00001067 | 4.33e-03 |
| 9792 | COLEC12/OGN ratio | GCST90314184 | 4.31e-03 |
| 9793 | PDZK1 levels | GCST90470203 | 4.30e-03 |
| 9794 | ODAM levels | GCST90470115 | 4.30e-03 |
| 9795 | COLEC12/TAFA5 ratio | GCST90314185 | 4.28e-03 |
| 9796 | rfMRI amplitudes (ICA100 node 2) | GCST90004590 | 4.28e-03 |
| 9797 | DTI TBSS MD Body of corpus callosum | GCST90384575 | 4.26e-03 |
| 9798 | COL28A1 levels | GCST90468815 | 4.26e-03 |
| 9799 | Synonym | Fluid intelligence / reasoning | UKBB00000802 | 4.25e-03 |
| 9800 | aseg lh volume Pallidum | GCST90002623 | 4.24e-03 |
| 9801 | Right-hemisphere dorsal attention network to hippocampus white-matter structural connectivity | GCST90302810 | 4.24e-03 |
| 9802 | ICAM2/SELE ratio | GCST90315120 | 4.22e-03 |
| 9803 | Omega-3 fatty acids to total fatty acids percentage | GCST90502450 | 4.21e-03 |
| 9804 | Other demyelinating diseases of the central nervous system | FING00000995 | 4.20e-03 |
| 9805 | PODXL2 levels | GCST90470279 | 4.20e-03 |
| 9806 | Basal cell carcinoma (MTAG) | GCST90137411 | 4.19e-03 |
| 9807 | AmygNuclei rh volume Cortical-nucleus | GCST90002664 | 4.18e-03 |
| 9808 | Diarrhoea and gastroenteritis of presumed infectious origin | FING00000420 | 4.18e-03 |
| 9809 | CASP8/RILP ratio | GCST90313657 | 4.17e-03 |
| 9810 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T431 | ECGU000431 | 4.16e-03 |
| 9811 | X-08402 levels | GCST90243538 | 4.15e-03 |
| 9812 | Lichen sclerosus et atrophicus | FING00000723 | 4.13e-03 |
| 9813 | Malignant neoplasm of female breast | neoplasms | UKBB00000426 | 4.13e-03 |
| 9814 | Saturated fatty acids to total fatty acids percentage | GCST90502696 | 4.13e-03 |
| 9815 | ST13 levels | GCST90470751 | 4.12e-03 |
| 9816 | Lysine levels | GCST90200402 | 4.12e-03 |
| 9817 | DNAJB6 levels | GCST90469014 | 4.11e-03 |
| 9818 | Vitiligo | FING00001443 | 4.11e-03 |
| 9819 | TIMP3 levels | GCST90470871 | 4.10e-03 |
| 9820 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T486 | ECGA000486 | 4.10e-03 |
| 9821 | Facial pigmentation measurement (UV light) | GCST90002283 | 4.09e-03 |
| 9822 | Other non-toxic goitre | Disorders of thyroid gland | UKBB00000617 | 4.08e-03 |
| 9823 | RBP2 levels | GCST90470438 | 4.07e-03 |
| 9824 | GSTA1 levels | GCST90469411 | 4.07e-03 |
| 9825 | BAG6 levels | GCST90468418 | 4.07e-03 |
| 9826 | Valine levels | GCST90500177 | 4.06e-03 |
| 9827 | Depression/anxiety (standard GWA) | GCST90267276 | 4.05e-03 |
| 9828 | All dysplastic lesions of the cervix uteri | FING00000060 | 4.05e-03 |
| 9829 | Hair colour (natural, before greying): Dark brown (UKB data field 1747_4) | GCST90041839 | 4.03e-03 |
| 9830 | LILRB4 levels | GCST90426708 | 4.03e-03 |
| 9831 | CTRC levels | GCST90468906 | 4.03e-03 |
| 9832 | NRCAM/PCDH17 ratio | GCST90315553 | 4.02e-03 |
| 9833 | Migraine (PheCode 340) | GCST90475837 | 4.02e-03 |
| 9834 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T490 | ECGA000490 | 4.01e-03 |
| 9835 | Phosphatidylcholine-O_38:5_[M+H]1+/Phosphatidylcholine-P_38:4_[M+H]1+ levels | GCST90060375 | 4.01e-03 |
| 9836 | Physical activity (Principal component 2) | GCST90061423 | 4.00e-03 |
| 9837 | MESD/VASH1 ratio | GCST90315425 | 3.99e-03 |
| 9838 | BTN2A1/CSF1 ratio | GCST90313541 | 3.98e-03 |
| 9839 | Multiple sclerosis | GCST90475833 | 3.94e-03 |
| 9840 | CDKN2D/TACC3 ratio | GCST90313992 | 3.90e-03 |
| 9841 | FCAMR levels | GCST90469196 | 3.88e-03 |
| 9842 | SNX5 levels | GCST90470702 | 3.88e-03 |
| 9843 | INPPL1 levels | GCST90469619 | 3.87e-03 |
| 9844 | ANKMY2 levels | GCST90468309 | 3.87e-03 |
| 9845 | Left-hemisphere somatomotor network to thalamus white-matter structural connectivity | GCST90302682 | 3.87e-03 |
| 9846 | FAM174A levels | GCST90241914 | 3.87e-03 |
| 9847 | O-sulfo-l-tyrosine levels | GCST90243623 | 3.87e-03 |
| 9848 | TEK levels | GCST90012013 | 3.86e-03 |
| 9849 | CD86 levels | GCST90468654 | 3.85e-03 |
| 9850 | CANT1/VSIR ratio | GCST90313621 | 3.85e-03 |
| 9851 | CA11 levels | GCST90468506 | 3.84e-03 |
| 9852 | ANGPT1 levels | GCST90468300 | 3.83e-03 |
| 9853 | Any mental disorder, or suicide (or attempt), or psychic disorders complicating pregnancy, partum or puerperium or nerve system disorders (more control exclusions) | FING00000101 | 3.79e-03 |
| 9854 | Facial skin colour (CIELAB index b* value) | GCST90020056 | 3.78e-03 |
| 9855 | FLT4 levels | GCST90469252 | 3.78e-03 |
| 9856 | AHCY levels | GCST90468259 | 3.77e-03 |
| 9857 | SERPINA9 levels | GCST90470588 | 3.76e-03 |
| 9858 | Systemic lupus erythematosus | GCST90011866 | 3.73e-03 |
| 9859 | CA4/PECAM1 ratio | GCST90313586 | 3.71e-03 |
| 9860 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 28) | GCST90320847 | 3.71e-03 |
| 9861 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T436 | ECGU000436 | 3.71e-03 |
| 9862 | Type of accommodation lived in - A flat, maisonette or apartment | Household | UKBB00000868 | 3.70e-03 |
| 9863 | Cystatin C production | GCST90267986 | 3.70e-03 |
| 9864 | Omega-3 fatty acids levels | GCST90499139 | 3.70e-03 |
| 9865 | Noninfectious gastroenteritis | digestive | UKBB00000526 | 3.69e-03 |
| 9866 | ENPP7 levels | GCST90469118 | 3.68e-03 |
| 9867 | 3-amino-2-piperidone levels | GCST90200188 | 3.67e-03 |
| 9868 | ANXA1 levels | GCST90240296 | 3.63e-03 |
| 9869 | Nasal polyp | Other diseases of upper respiratory tract | UKBB00000493 | 3.63e-03 |
| 9870 | SPART levels | GCST90470719 | 3.63e-03 |
| 9871 | Takes medication for asthma? | GCST90475260 | 3.62e-03 |
| 9872 | DNMBP levels | GCST90469023 | 3.61e-03 |
| 9873 | LILRB2 levels | GCST90469777 | 3.60e-03 |
| 9874 | Primary angle-closure glaucoma | FING00001210 | 3.60e-03 |
| 9875 | BST1 levels | GCST90468474 | 3.58e-03 |
| 9876 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T482 | ECGA000482 | 3.58e-03 |
| 9877 | N-formylmethionine levels | GCST90200343 | 3.57e-03 |
| 9878 | ANXA3/BID ratio | GCST90313279 | 3.57e-03 |
| 9879 | CXCL17/LAMP3 ratio | GCST90314340 | 3.54e-03 |
| 9880 | Depressive symptomatology (confirmatory factor analysis Factor 2) | GCST90309337 | 3.53e-03 |
| 9881 | TP53I3 levels | GCST90470937 | 3.53e-03 |
| 9882 | SNAP29/SPARC ratio | GCST90315860 | 3.53e-03 |
| 9883 | CD59/SCARB2 ratio | GCST90313859 | 3.51e-03 |
| 9884 | IDP T1 FAST ROIs L front operc cortex | GCST90002531 | 3.51e-03 |
| 9885 | IDP dMRI TBSS FA Fornix | GCST90003882 | 3.51e-03 |
| 9886 | VNN2 levels | GCST90471044 | 3.49e-03 |
| 9887 | CLIP2 levels | GCST90468782 | 3.48e-03 |
| 9888 | SIRT1 levels | GCST90470641 | 3.48e-03 |
| 9889 | Scar conditions and fibrosis of skin (PheCode 701.2) | GCST90476198 | 3.48e-03 |
| 9890 | SSNA1 levels | GCST90470750 | 3.48e-03 |
| 9891 | Malignant melanoma of skin, excluding all cancers (controls excluding all cancers) | FING00000749 | 3.48e-03 |
| 9892 | Lysoalkylphosphatidylcholine (O-24:0) levels | GCST90024812 | 3.47e-03 |
| 9893 | Working memory | GCST90503116 | 3.47e-03 |
| 9894 | Stearoylcarnitine (C18) levels | GCST90199743 | 3.44e-03 |
| 9895 | Type of accommodation lived in - A house or bungalow | Household | UKBB00000869 | 3.44e-03 |
| 9896 | CDH17/PECAM1 ratio | GCST90313942 | 3.42e-03 |
| 9897 | CCN2/MGLL ratio | GCST90313714 | 3.42e-03 |
| 9898 | ENO2/TACC3 ratio | GCST90314670 | 3.42e-03 |
| 9899 | Erythematosquamous dermatosis (PheCode 690) | GCST90476170 | 3.41e-03 |
| 9900 | aparc-a2009s lh volume G-pariet-inf-Supramar | GCST90002950 | 3.41e-03 |
| 9901 | Other follicular disorders | FING00001050 | 3.40e-03 |
| 9902 | OLFM4 levels | GCST90470121 | 3.40e-03 |
| 9903 | F7/VASN ratio | GCST90314745 | 3.40e-03 |
| 9904 | Fasting glucose | GCST90278628 | 3.40e-03 |
| 9905 | Degree of unsaturation | GCST90502752 | 3.39e-03 |
| 9906 | BECN1 levels | GCST90468438 | 3.39e-03 |
| 9907 | SERPINE1/USP8 ratio | GCST90315835 | 3.39e-03 |
| 9908 | Coeliac disease | GCST90468120 | 3.38e-03 |
| 9909 | Other diseases of the digestive system | FING00001010 | 3.38e-03 |
| 9910 | ANXA4/CA13 ratio | GCST90313290 | 3.38e-03 |
| 9911 | Right-hemisphere control network to thalamus white-matter structural connectivity | GCST90302836 | 3.37e-03 |
| 9912 | CLMP levels | GCST90468783 | 3.37e-03 |
| 9913 | SLC4A1 levels | GCST90470663 | 3.35e-03 |
| 9914 | ANXA4/LACTB2 ratio | GCST90313293 | 3.34e-03 |
| 9915 | F-strong flavour liking (derived food-liking factor) | GCST90094851 | 3.34e-03 |
| 9916 | Pulmonary embolism | GCST90468148 | 3.34e-03 |
| 9917 | NPPC levels | GCST90470075 | 3.34e-03 |
| 9918 | TNFRSF14/TNFSF14 ratio | GCST90315936 | 3.34e-03 |
| 9919 | Infections of the skin and subcutaneous tissue | FING00000670 | 3.33e-03 |
| 9920 | Operative procedures - Carpal tunnel release | Summary Operations | UKBB00000574 | 3.32e-03 |
| 9921 | CDH5/TEK ratio | GCST90313961 | 3.32e-03 |
| 9922 | Malignant neoplasm of bladder, excluding all cancers (controls excluding all cancers) | FING00000751 | 3.31e-03 |
| 9923 | Carnitine levels | GCST90199621 | 3.31e-03 |
| 9924 | HNMT levels | GCST90469468 | 3.31e-03 |
| 9925 | SELL levels | GCST90470567 | 3.30e-03 |
| 9926 | Phosphatidylcholine-O_34:3_[M+H]1+/Phosphatidylcholine-P_34:2_[M+H]1+/Phosphatidylethanolamine-P_37:2_[M+H]1+ levels | GCST90060277 | 3.30e-03 |
| 9927 | STAMBP/WWP2 ratio | GCST90315888 | 3.29e-03 |
| 9928 | Avoided activities or situations because of previous stressful experience in past month | Traumatic events | UKBB00000083 | 3.29e-03 |
| 9929 | red blood cell count (RBC, maximum, inv-norm transformed) | GCST90476345 | 3.28e-03 |
| 9930 | Eicosenoylcarnitine (C20:1) levels | GCST90200148 | 3.28e-03 |
| 9931 | Omega-6 fatty acid levels | GCST90092933 | 3.27e-03 |
| 9932 | IL17D levels | GCST90469560 | 3.27e-03 |
| 9933 | MYO9B levels | GCST90469982 | 3.26e-03 |
| 9934 | Biological Mother: High blood pressure | GCST90475490 | 3.25e-03 |
| 9935 | EIF4G1/NFATC1 ratio | GCST90314637 | 3.22e-03 |
| 9936 | Volume of left paralaminar nucleus | GCST90474985 | 3.21e-03 |
| 9937 | Seborrheic dermatitis (PheCode 690.1) | GCST90476171 | 3.20e-03 |
| 9938 | Cerebrospinal fluid proline levels | GCST90318251 | 3.20e-03 |
| 9939 | IL18RAP levels | GCST90469566 | 3.19e-03 |
| 9940 | Omega-3 fatty acids to total fatty acids percentage | GCST90502462 | 3.18e-03 |
| 9941 | RPE levels | GCST90470495 | 3.18e-03 |
| 9942 | rfMRI amplitudes (ICA100 node 28) | GCST90004616 | 3.18e-03 |
| 9943 | METAP2/PFKFB2 ratio | GCST90315431 | 3.18e-03 |
| 9944 | NUCB2 levels | GCST90470101 | 3.18e-03 |
| 9945 | Skin color (cheek, ITA value) | GCST90502780 | 3.17e-03 |
| 9946 | 1-ribosyl-imidazoleacetate levels | GCST90199815 | 3.16e-03 |
| 9947 | COX5B/GFER ratio | GCST90314200 | 3.16e-03 |
| 9948 | T1 FreeSurfer aseg Left-Pallidum | GCST90384146 | 3.13e-03 |
| 9949 | ADH4/CA5A ratio | GCST90313189 | 3.10e-03 |
| 9950 | Illnesses of siblings - None of the above (group 1) | Family history | UKBB00000353 | 3.10e-03 |
| 9951 | CLEC11A levels | GCST90468764 | 3.07e-03 |
| 9952 | Malignant neoplasm of breast | Malignant neoplasm of breast | UKBB00000424 | 3.06e-03 |
| 9953 | neutrophil (fraction, maximum, inv-norm transformed) | GCST90475535 | 3.04e-03 |
| 9954 | Other/unspecified dorsalgia | FING00001124 | 3.04e-03 |
| 9955 | FCER2 levels | GCST90469199 | 3.04e-03 |
| 9956 | Feeling fed-up | GCST006947 | 3.04e-03 |
| 9957 | Nasal polyps | GCST90468143 | 3.03e-03 |
| 9958 | Operative procedures - Endoscopic resection of semilunar cartilage NEC | Summary Operations | UKBB00000577 | 3.02e-03 |
| 9959 | ANXA3/SERPINB1 ratio | GCST90313289 | 3.02e-03 |
| 9960 | CSNK2A1 or CSNK2B levels | GCST90088963 | 3.02e-03 |
| 9961 | eGFR in diabetes mellitus (strict) case-control group (minimal adjustment) | GCST90624781 | 3.02e-03 |
| 9962 | End-diastolic bi-ventricular shape (principal component 4) | GCST90448483 | 3.01e-03 |
| 9963 | PDGFB/SPINT2 ratio | GCST90315629 | 3.01e-03 |
| 9964 | Right-hemisphere visual network to right-hemisphere control network white-matter structural connectivity | GCST90302779 | 3.00e-03 |
| 9965 | DAG1/MGLL ratio | GCST90314377 | 3.00e-03 |
| 9966 | Lamb or mutton consumption (UKB data field 1379) | GCST90132998 | 2.99e-03 |
| 9967 | CDH1/CST3 ratio | GCST90313946 | 2.98e-03 |
| 9968 | IDP dMRI TBSS OD Anterior limb of internal capsule R | GCST90004418 | 2.98e-03 |
| 9969 | FIS1/PDGFB ratio | GCST90314830 | 2.98e-03 |
| 9970 | MMP1/MMP3 ratio | GCST90315461 | 2.97e-03 |
| 9971 | CD300LF levels | GCST90468622 | 2.97e-03 |
| 9972 | ITGB6 levels | GCST90469646 | 2.97e-03 |
| 9973 | T1 FreeSurfer a2009s lh S postcentral area | GCST90384734 | 2.96e-03 |
| 9974 | Left-hemisphere default mode network to putamen white-matter structural connectivity | GCST90302769 | 2.95e-03 |
| 9975 | Psoriatic arthropathies | FING00001225 | 2.93e-03 |
| 9976 | Prevotellamassilia abundance in stool | GCST90032517 | 2.93e-03 |
| 9977 | ST3GAL1 levels | GCST90470752 | 2.90e-03 |
| 9978 | Other malignant neoplasms of skin | Melanoma and other malignant neoplasms of skin | UKBB00000613 | 2.88e-03 |
| 9979 | Cancer of prostate (PheCode 185) | GCST90041853 | 2.88e-03 |
| 9980 | METAP2/USP8 ratio | GCST90315434 | 2.87e-03 |
| 9981 | Urea | Blood biochemistry | UKBB00000885 | 2.86e-03 |
| 9982 | Other and unspecified tonsillitis | FING00000954 | 2.86e-03 |
| 9983 | Otitis externa | FING00001128 | 2.86e-03 |
| 9984 | Takes medication for skin cancer? | GCST90475190 | 2.85e-03 |
| 9985 | Single spontaneous delivery | FING00001307 | 2.85e-03 |
| 9986 | CMIP levels | GCST90468795 | 2.85e-03 |
| 9987 | TCL1A levels | GCST90470817 | 2.85e-03 |
| 9988 | PLA2G4A/SNAP29 ratio | GCST90315669 | 2.84e-03 |
| 9989 | Childhood asthma (age<16) (more control exclusions) | FING00000270 | 2.84e-03 |
| 9990 | Glaucoma (PheCode 365) | GCST008373 | 2.83e-03 |
| 9991 | ARHGEF12/DECR1 ratio | GCST90313349 | 2.82e-03 |
| 9992 | LPCAT2/SERPINB8 ratio | GCST90315328 | 2.82e-03 |
| 9993 | Lawsonibacter sp002161175 abundance in stool | GCST90032459 | 2.80e-03 |
| 9994 | PACS2 levels | GCST90470141 | 2.80e-03 |
| 9995 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 102) | GCST90320921 | 2.79e-03 |
| 9996 | Normal-pressure hydrocephalus | FING00000891 | 2.79e-03 |
| 9997 | SIAE levels | GCST90470629 | 2.78e-03 |
| 9998 | Breast size | GCST006655 | 2.78e-03 |
| 9999 | PPP2R5A levels | GCST90470306 | 2.78e-03 |
| 10000 | SNAP23/SNAP29 ratio | GCST90315855 | 2.78e-03 |